Maverick Citizen Study shows six-monthly anti-HIV jab could end Aids in South Africa by 2032 8 min 0 By Mia Malan
Maverick Citizen The Global Fund will roll out the twice-yearly anti-HIV jab — with or without Pepfar 7 min 0 By Ida Jooste
Maverick Citizen US embassy confirms Pepfar projects will restart — despite Trump’s aid ban in SA 5 min 0 By Mia Malan
Maverick Citizen Viatris launches local ARV production in South Africa: a game changer for HIV treatment accessibility 3 min 0 By Naledi Sikhakhane
Op-eds South Africa's HIV challenge: progress towards 2030 goals requires urgent action and innovation 5 min 0 By Salim Abdool Karim and Nikita Devnarain for Spotlight
Maverick Citizen A call for urgent action in navigating the complex landscape of long-acting HIV medications 7 min 1 By Francois Venter
Op-eds How South Africa can help secure immediate, global access to HIV prevention drug lenacapavir 4 min 1 By Tian Johnson, Fatima Hassan, Asia Russell and Sangeeta Shashikant
Maverick Citizen Talks have started to get the twice-yearly anti-HIV jab registered in SA 7 min 1 By Mia Malan
Maverick Citizen Efficacy of six-monthly HIV prevention jab confirmed in second major study 9 min 0 By Elri Voigt for Spotlight
Maverick Citizen Almost 40% of the world’s anti-HIV pill users live in South Africa 9 min 2 By Mia Malan, Linda Pretorius and Zano Kunene
Op-eds Empowering girls, ending HIV — a call to action on International Day of the Girl Child 4 min 0 By Eva Kiwango
Maverick Citizen Why we don’t have long-acting HIV treatment in South Africa 7 min 0 By Elri Voigt for Spotlight
Maverick Citizen Aids 2024 — exciting developments with the jabs promising to revolutionise HIV prevention 7 min 0 By Elri Voigt for Spotlight
Maverick Citizen Lenacapavir — what it would it take to get the six-monthly anti-HIV jab to South Africa 8 min 0 By Mia Malan and Linda Pretorius
Maverick Citizen Twice-yearly HIV prevention shot succeeds in pivotal trial, but questions loom over future access 7 min 0 By Thabo Molelekwa and Marcus Low for Spotlight
